{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:31:47Z","timestamp":1792794707163,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00393-025-01737-6","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:23:05Z","timestamp":1758730985000},"page":"403-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy and safety of denosumab biosimilar and originator in postmenopausal osteoporosis: a\u00a0meta-analysis of randomized controlled trials","Vergleich der Wirksamkeit und Sicherheit von Denosumab-Biosimilar und Originalpr\u00e4parat bei postmenopausaler Osteoporose: eine Metaanalyse randomisierter kontrollierter Studien"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-1909","authenticated-orcid":false,"given":"Young Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwan Gyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"1737_CR1","doi-asserted-by":"crossref","unstructured":"Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM (2018) A\u00a0comprehensive overview on osteoporosis and its risk factors. TCRM: 2029\u20132049","DOI":"10.2147\/TCRM.S138000"},{"issue":"3","key":"1737_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4078\/jrd.2023.0009","volume":"30","author":"SG Cengiz","year":"2023","unstructured":"Cengiz\u00a0SG, Kaplan\u00a0H (2023) The effect of central sensitization on disease activity measures, quality of life and clinical parameters in axial spondyloarthritis: a\u00a0cross-sectional study. J\u00a0Rheum Dis 30(3):176\u2013184","journal-title":"J Rheum Dis"},{"issue":"7","key":"1737_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1177\/154405910608500703","volume":"85","author":"U Lerner","year":"2006","unstructured":"Lerner\u00a0U (2006) Bone remodeling in post-menopausal osteoporosis. J\u00a0Dent Res 85(7):584\u2013595","journal-title":"J Dent Res"},{"issue":"2","key":"1737_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4078\/jrd.2023.0043","volume":"31","author":"S-H Kim","year":"2024","unstructured":"Kim\u00a0S\u2011H, Choi\u00a0H\u2011J, Lee\u00a0S\u2011M, Yoon\u00a0DS, Son\u00a0C\u2011N (2024) Effect of recombinant human bone morphogenetic protein\u20112 and osteoprotegerin-Fc in MC3T3-E1 cells. J\u00a0Rheum Dis 31(2):79\u201385","journal-title":"J Rheum Dis"},{"issue":"37","key":"1737_CR5","doi-asserted-by":"publisher","first-page":"6356","DOI":"10.2174\/0929867326666190730113123","volume":"27","author":"M De Martinis","year":"2020","unstructured":"De Martinis\u00a0M, Sirufo\u00a0MM, Ginaldi\u00a0L (2020) Osteoporosis: current and emerging therapies targeted to immunological checkpoints. CMC 27(37):6356\u20136372","journal-title":"CMC"},{"issue":"7","key":"1737_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone\u00a0HG, Wagman\u00a0RB, Brandi\u00a0ML, Brown\u00a0JP, Chapurlat\u00a0R, Cummings\u00a0SR et\u00a0al (2017) 10\u00a0years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase\u00a03 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1737_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/ph17020235","volume":"17","author":"F Mascarenhas-Melo","year":"2024","unstructured":"Mascarenhas-Melo\u00a0F, Diaz\u00a0M, Gon\u00e7alves\u00a0MBS, Vieira\u00a0P, Bell\u00a0V, Viana\u00a0S et\u00a0al (2024) An overview of biosimilars\u2014development, quality, regulatory issues, and management in healthcare. Pharmaceuticals 17(2):235","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1737_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/ijp.IJP_346_19","volume":"53","author":"I Singh","year":"2021","unstructured":"Singh\u00a0I, Jose\u00a0V, Patel\u00a0R, Arora\u00a0S, Team IS\u2011I (2021) Denosumab biosimilar in postmenopausal osteoporotic women: a\u00a0randomized, assessor-blind, active-controlled clinical trial. Indian J Pharmacol 53(1):6\u201312","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"1737_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13075-022-02840-8","volume":"24","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi\u00a0A, Vojdanian\u00a0M, Soroush\u00a0M, Akbarian\u00a0M, Aghaei\u00a0M, Hajiabbasi\u00a0A et\u00a0al (2022) Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia\u00ae) in postmenopausal osteoporosis: a\u00a0phase\u00a0III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial. Arthritis Res Ther 24(1):161","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1737_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/jbmr\/zjae016","volume":"39","author":"S Jeka","year":"2024","unstructured":"Jeka\u00a0S, Dokoupilov\u00e1\u00a0E, Kivitz\u00a0A, \u017buchowski\u00a0P, Vogg\u00a0B, Krivtsova\u00a0N et\u00a0al (2024) Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. J\u00a0Bone Miner Res 39(3):202\u2013210","journal-title":"J Bone Miner Res"},{"key":"1737_CR11","unstructured":"Reginster J\u2011Y, Silverman SL, Czerwinski E, Borowy P, Budlewski T, Kwiatek J et\u00a0al (2024) Efficacy and safety results of CT-P41 (proposed Denosumab Biosimilar) compared to reference denosumab (Prolia) in postmenopausal women with osteoporosis: 78-week results from phase\u00a03 randomized controlled trial. ASBMR 2024 Annu Meet ASBMR"},{"key":"1737_CR12","doi-asserted-by":"publisher","first-page":"117371","DOI":"10.1016\/j.bone.2024.117371","volume":"192","author":"Y-S Chung","year":"2025","unstructured":"Chung\u00a0Y\u2011S, Langdahl\u00a0B, Plebanski\u00a0R, Czerwinski\u00a0E, Dokoupilova\u00a0E, Supronik\u00a0J et\u00a0al (2025) SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a\u00a0phase\u00a0III randomized clinical trial. Bone 192:117371","journal-title":"Bone"},{"issue":"1","key":"1737_CR13","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.59556\/japi.73.0772","volume":"73","author":"T Paul","year":"2025","unstructured":"Paul\u00a0T, Garg\u00a0B, Kapoor\u00a0N, Patil\u00a0V, Kachnerkar\u00a0N, Shembalkar\u00a0J et\u00a0al (2025) A\u00a0prospective, active-controlled, randomized, double-blind, multicenter, phase\u00a0III study to compare the safety and efficacy of biosimilar denosumab vs reference denosumab in the treatment of postmenopausal osteoporosis. J\u00a0Assoc Physicians India 73(1):e8\u2013e13","journal-title":"J Assoc Physicians India"},{"issue":"1","key":"1737_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4078\/jrd.2024.0095","volume":"32","author":"YH Lee","year":"2025","unstructured":"Lee\u00a0YH, Song\u00a0GG (2025) Associations between circulating interleukin-18\u00a0levels and adult-onset still\u2019s disease: a\u00a0meta-analysis. J\u00a0Rheum Dis 32(1):48\u201356","journal-title":"J Rheum Dis"},{"issue":"2","key":"1737_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4078\/jrd.2023.0059","volume":"31","author":"P Waitayangkoon","year":"2024","unstructured":"Waitayangkoon\u00a0P, Leesutipornchai\u00a0T, Techasatian\u00a0W, Aiumtrakul\u00a0N, Tanariyakul\u00a0M, Arayangkool\u00a0C et\u00a0al (2024) Urate-lowering therapy is associated with a\u00a0reduced risk of arrhythmias: a\u00a0systematic review and meta-analysis. J\u00a0Rheum Dis 31(2):108\u2013115","journal-title":"J Rheum Dis"},{"issue":"2","key":"1737_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4078\/jrd.2024.0103","volume":"32","author":"YH Lee","year":"2025","unstructured":"Lee\u00a0YH, Song\u00a0GG (2025) Circulating VEGF levels and genetic polymorphisms in Behçet’s disease: a\u00a0meta-analysis. J\u00a0Rheum Dis 32(2):122\u2013129","journal-title":"J Rheum Dis"},{"issue":"9085","key":"1737_CR17","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(05)63833-0","volume":"350","author":"DG Smith","year":"1997","unstructured":"Smith\u00a0DG, Egger\u00a0M (1997) Meta-analyses of randomised controlled trials. Lancet 350(9085):1182","journal-title":"Lancet"},{"issue":"11","key":"1737_CR18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins\u00a0JP, Thompson\u00a0SG (2002) Quantifying heterogeneity in a\u00a0meta-analysis. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"issue":"2","key":"1737_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3904\/kjim.2016.195","volume":"33","author":"YH Lee","year":"2017","unstructured":"Lee\u00a0YH (2017) An overview of meta-analysis for clinicians. Korean J Intern Med 33(2):277","journal-title":"Korean J Intern Med"},{"issue":"7109","key":"1737_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger\u00a0M, Smith\u00a0DG, Schneider\u00a0M, Minder\u00a0C (1997) Bias in meta-analysis detected by a\u00a0simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"key":"1737_CR21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00198-018-4741-0","volume":"30","author":"I Tak\u00e1cs","year":"2019","unstructured":"Tak\u00e1cs\u00a0I, J\u00f3kai\u00a0E, Kov\u00e1ts\u00a0D, Aradi\u00a0I (2019) The first biosimilar approved for the treatment of osteoporosis: results of a\u00a0comparative pharmacokinetic\/pharmacodynamic study. Osteoporos Int 30:675\u2013683","journal-title":"Osteoporos Int"},{"key":"1737_CR22","doi-asserted-by":"crossref","unstructured":"Jarab AS, Heshmeh ASR, Al Meslamani AZ (2025) Biosimilars and immunogenicity: a\u00a0matter of concern? Expert Opin Drug Saf: 1\u20139","DOI":"10.1080\/14740338.2025.2467817"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01737-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01737-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01737-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:28:27Z","timestamp":1780482507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01737-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01737-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"24 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.H.\u00a0Lee and G.G.\u00a0Song declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"An ethics statement is not applicable because this study is based exclusively on published literature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}